NCT04334980View on ClinicalTrials.gov

Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

bacTRL-Spike

Each oral dose of bacTRL-Spike contains bacterial medium with either 1 billion (Group 1), 3 billion (Group 2) or 10 billion (Group 3) colony-forming-units of live Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.

Trial Locations (1)

3004

Nucleus Network Pty Ltd Brisbane (QPharm), Brisbane

All Listed Sponsors
lead

Symvivo Corporation

INDUSTRY

NCT04334980 - Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 | Biotech Hunter | Biotech Hunter